Tadliq (Tadalafil) for Pulmonary Hypertension

Overview
Tadliq is approved by the U.S. Food and Drug Administration (FDA) for the treatment of pulmonary arterial hypertension (PAH) Group 1. It is prescribed to improve exercise ability in individuals with PAH. Tadliq is also known by its drug name, tadalafil.

Tadliq belongs to a class of drugs called phosphodiesterase 5 (PDE5) inhibitors. It works by relaxing the blood vessels in the lungs, which reduces blood pressure and improves blood flow, making it easier for the heart to pump blood through the lungs.

How do I take it?
Prescribing information states that Tadliq is typically taken as an oral suspension once daily, with or without food. If used with certain medications, such as ritonavir, dose adjustments may be required. Tadliq should be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Tadliq include headache.

Rare but serious side effects may include hypotension (low blood pressure), sudden loss of vision (which may be a sign of non-arteritic ischemic optic neuropathy, or NAION), sudden hearing loss, and priapism (prolonged erections lasting more than four hours). In some cases, Tadliq may worsen symptoms in individuals with pulmonary veno-occlusive disease.

For more information about this treatment, visit:

Label: Tadliq — Tadalafil Suspension — DailyMed